Ndyomugyenyi R
National Onchocerciasis Control Programme, Ministry of Health, Kampala, Uganda.
Ann Trop Med Parasitol. 1998 Apr;92 Suppl 1:S133-7. doi: 10.1080/00034989859672.
Onchocerciasis is far more prevalent and far more of a public-health and socio-economic problem in Uganda than it was thought to be a decade ago. It appears that over a million Ugandans have the disease and nearly two million others live in endemic areas. A few years of annual treatment with Mectizan (ivermectin, MSD) have reduced the community microfilarial load (CMFL) in sentinel villages in Uganda by 52%-100%. The greatest reductions (100%) have been in those villages with the lower CMFL pre-treatment. Assessments at intervals of much less than 1 year should help to show how quickly skin cleared by Mectizan is re-invaded by microfilariae and give an idea of how frequently treatment should be given to produce the greatest benefits. It seems likely that it would be best to give Mectizan at intervals of < 1 year and that such frequent treatment only becomes feasible if Mectizan distribution is community-directed.
盘尾丝虫病在乌干达的流行程度远比十年前人们认为的要高得多,并且它更是一个公共卫生和社会经济问题。似乎有超过100万乌干达人感染了这种疾病,另有近200万人生活在流行地区。连续几年使用美迪生(伊维菌素,默克雪兰诺公司生产)进行年度治疗,已使乌干达哨点村庄的社区微丝蚴负荷(CMFL)降低了52% - 100%。降幅最大(100%)的是那些治疗前CMFL较低的村庄。间隔远小于1年进行评估,应有助于显示经美迪生清除微丝蚴的皮肤被重新感染的速度,并能了解应多频繁地进行治疗才能产生最大益处。似乎最好每隔不到1年使用一次美迪生,并且只有在以社区为导向分发美迪生的情况下,这种频繁治疗才可行。